145 related articles for article (PubMed ID: 26276435)
21. Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
Li X; Lu X; Chen W; Liu H; Zhan P; Pannecouque C; Balzarini J; De Clercq E; Liu X
Bioorg Med Chem; 2014 Oct; 22(19):5290-7. PubMed ID: 25150090
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors.
Čechová L; Dejmek M; Baszczyňski O; Šaman D; Gao L; Hu E; Stepan G; Jansa P; Janeba Z; Šimon P
Antivir Chem Chemother; 2019; 27():2040206619826265. PubMed ID: 30788976
[TBL] [Abstract][Full Text] [Related]
23. Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.
Mugnaini C; Alongi M; Togninelli A; Gevariya H; Brizzi A; Manetti F; Bernardini C; Angeli L; Tafi A; Bellucci L; Corelli F; Massa S; Maga G; Samuele A; Facchini M; Clotet-Codina I; Armand-Ugón M; Esté JA; Botta M
J Med Chem; 2007 Dec; 50(26):6580-95. PubMed ID: 18052319
[TBL] [Abstract][Full Text] [Related]
24. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Ma XD; Zhang X; Dai HF; Yang SQ; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE
Bioorg Med Chem; 2011 Aug; 19(15):4601-7. PubMed ID: 21719299
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.
Sun Y; Kang D; Da F; Zhang T; Li P; Zhang B; De Clercq E; Pannecouque C; Zhan P; Liu X
Eur J Med Chem; 2021 Mar; 214():113204. PubMed ID: 33567378
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Yu M; Fan E; Wu J; Liu X
Curr Med Chem; 2011; 18(16):2376-85. PubMed ID: 21568919
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Qin H; Liu C; Zhang J; Guo Y; Zhang S; Zhang Z; Wang X; Zhang L; Liu J
Bioorg Med Chem Lett; 2010 May; 20(9):3003-5. PubMed ID: 20347295
[TBL] [Abstract][Full Text] [Related]
29. Development of Novel Dihydrofuro[3,4-
Kang D; Sun Y; Feng D; Gao S; Wang Z; Jing L; Zhang T; Jiang X; Lin H; De Clercq E; Pannecouque C; Zhan P; Liu X
J Med Chem; 2022 Feb; 65(3):2458-2470. PubMed ID: 35061384
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase.
Wang Z; Vince R
Bioorg Med Chem Lett; 2008 Feb; 18(4):1293-6. PubMed ID: 18226894
[TBL] [Abstract][Full Text] [Related]
31. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
Tian Y; Du D; Rai D; Wang L; Liu H; Zhan P; De Clercq E; Pannecouque C; Liu X
Bioorg Med Chem; 2014 Apr; 22(7):2052-9. PubMed ID: 24631361
[TBL] [Abstract][Full Text] [Related]
32. Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogues.
Wang Y; Chen FE; Balzarini J; De Clercq E; Pannecouque C
Chem Biodivers; 2008 Jan; 5(1):168-76. PubMed ID: 18205120
[TBL] [Abstract][Full Text] [Related]
33. Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
Mao TQ; He QQ; Wan ZY; Chen WX; Chen FE; Tang GF; De Clercq E; Daelemans D; Pannecouque C
Bioorg Med Chem; 2015 Jul; 23(13):3860-8. PubMed ID: 25907370
[TBL] [Abstract][Full Text] [Related]
34. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
Sergeyev S; Yadav AK; Franck P; Michiels J; Lewi P; Heeres J; Vanham G; Ariën KK; Vande Velde CM; De Winter H; Maes BU
J Med Chem; 2016 Mar; 59(5):1854-68. PubMed ID: 26785139
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
Mugnaini C; Manetti F; Esté JA; Clotet-Codina I; Maga G; Cancio R; Botta M; Corelli F
Bioorg Med Chem Lett; 2006 Jul; 16(13):3541-4. PubMed ID: 16621553
[TBL] [Abstract][Full Text] [Related]
36. Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
Manetti F; Esté JA; Clotet-Codina I; Armand-Ugón M; Maga G; Crespan E; Cancio R; Mugnaini C; Bernardini C; Togninelli A; Carmi C; Alongi M; Petricci E; Massa S; Corelli F; Botta M
J Med Chem; 2005 Dec; 48(25):8000-8. PubMed ID: 16335924
[TBL] [Abstract][Full Text] [Related]
37. Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
Kang D; Fang Z; Huang B; Lu X; Zhang H; Xu H; Huo Z; Zhou Z; Yu Z; Meng Q; Wu G; Ding X; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
J Med Chem; 2017 May; 60(10):4424-4443. PubMed ID: 28481112
[TBL] [Abstract][Full Text] [Related]
38. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
[TBL] [Abstract][Full Text] [Related]
39. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
40. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
